Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry

Launched by XUANWU HOSPITAL, BEIJING · Dec 25, 2018

Keywords

ClinConnect Summary

The Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry, or CoCCA, is a study designed to better understand patients who have experienced a stroke or a temporary stroke-like event called a transient ischemic attack (TIA). Specifically, it looks at people who have narrowing of blood vessels (called atherosclerosis) in both their brain and heart. The goal of this research is to identify risk factors and develop better ways to diagnose and treat these conditions, ultimately improving patient care.

To participate in this study, you must have been diagnosed with either an ischemic stroke or TIA within the last 30 days and have evidence of atherosclerosis in the brain and heart through specific imaging tests. The study is open to all adults ages 65 to 1045. If you join, you can expect to undergo some tests to confirm your eligibility and provide valuable information that could help improve treatment for future patients. Please note that individuals with certain serious health issues or those who prefer not to participate will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed as ischemic stroke or transient ischemic attack (TIA).
• • 2. Less than 30 days after onset of ischemic stroke or TIA symptoms.
• • 3. Extracranial or intracranial cerebral atherosclerosis confirmed by vascular ultrasound or CT angiograpgy or MR angiograpgy or digital substraction angiography.
• • 4. Coronary atherosclerosis confirmed by CT angiograpgy or MR angiograpgy or digital substraction angiography; or with myocardial ischemia symptoms confirmed using electrocardiogram or echocardiography or cardiac MR; or with a history of percutaneous coronary intervention or coronary artery bypass graft.
• Exclusion Criteria:
• • 1. With malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 5 years.
• • 2. Patients refuse to participate in the research.